Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy AdultsRecruiting
NCT07249463Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Cryptosporidiosis
United States
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTActive Not Recruiting
NCT05983198Phase 1Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Canada, France
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active Not Recruiting
NCT05985915Phase 3Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Sjogrens Syndrome
United States, Argentina, Australia, Austria, Belgium +30 more
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive Not Recruiting
NCT03876769Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
B-Cell Acute Lymphoblastic Leukemia
United States, Belgium, Canada, Denmark, France +6 more
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisRecruiting
NCT07604324Phase 1Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Dermatitis, Atopic
Japan
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Recruiting
NCT06632600Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Chagas Disease
United States, Argentina, Brazil, Colombia
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active Not Recruiting
NCT06042478Phase 3Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Argentina, Brazil, Bulgaria, Canada, Czechia +18 more
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesRecruiting
NCT06868212Phase 3Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU)
United States
Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast CancerCompleted
NCT05889728Phase 2Updated Aug 19, 2026
Sponsor: St Vincent's Hospital, Sydney
Breast Cancer
Australia
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)Recruiting
NCT06439082Phase 3Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Brazil, Colombia, Kenya, Uganda
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With AsthmaRecruiting
NCT05222529Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Asthma
Bulgaria, Colombia, Guatemala, Hungary, Poland +3 more
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruiting
NCT04104776Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant
United States, France, Italy, Poland, South Korea +2 more
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive Not Recruiting
NCT03701334Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +15 more
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active Not Recruiting
NCT05156281Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Brazil, Bulgaria, Canada +22 more
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompleted
NCT01742299Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
GIST and CML
United States, China, Finland, France, Hong Kong +6 more
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruiting
NCT07340190Phase 1Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies
France, Italy, Spain
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminated
NCT05853458Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Polycythemia Vera
Germany
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruiting
NCT07226986Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
United States, Australia, France, Germany, Italy +2 more
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive Not Recruiting
NCT04589650Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Canada, China, France, Germany +7 more
Secukinumab Open Label Roll-over Extension ProtocolRecruiting
NCT04638647Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Autoimmunity, Inflammation
United States, Brazil, Bulgaria, China, Colombia +15 more
Frontline Asciminib Combination in Chronic Phase CMLActive Not Recruiting
NCT03906292Phase 2Updated Aug 18, 2026
Sponsor: University of Jena
Chronic Myeloid Leukemia
Germany
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.Recruiting
NCT05948943Phase 2, Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Lymphatic Malformations
United States, Argentina, Australia, Belgium, Czechia +7 more
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompleted
NCT03106779Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
United States, Argentina, Australia, Brazil, Bulgaria +20 more
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active Not Recruiting
NCT07047118Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Cancer, Castration-Resistant
United States, Australia, Austria, Canada, China +10 more
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)Recruiting
NCT04485559Phase 1Updated Aug 18, 2026
Sponsor: University of California, San Francisco
Recurrent World Health Organization (WHO) Grade II Glioma · Low-grade Glioma · High-Grade Glioma (HGG)
United States

Previous page Next page